Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CASSANDRA phase 1/2 study of IDP-121 in relapsed or refractory hematologic malignancies
2024-519194-19-00Phase 2Authorised
- Sponsor
- IDP Discovery Pharma
- Start
- Dec 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of IDP-121 in mature B-cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and multiple myeloma (MM), sponsored by IDP Discovery Pharma. Primary endpoints: Maximum tolerated dose, Recommended phase 2 dose and 1 more. Planned start Dec 2024; status: authorised.
02
Drugs
IDP-121
03
Conditions
mature B-cell lymphomachronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-519194-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519194-19-00.